Cardiopulmonary syndrome and adrenoreactivity of an organism

Abstract

Aim. To study β-adrenoreactivity of the cell membrane in patients with different variants of heart failure in association with chronic obstructive pulmonary disease.

Methods. 120 heart failure patients including 68 of them who suffer from concominant chronic obstructive pulmonary disease were evaluated. Assessment of clinical features of heart failure, patients’ quality of life and study of β-adrenoreactivity were performed.

Results. Adrenoreactivity of an organism in heart failure and concominant chronic obstructive pulmonary disease was 2 times higher and was 55.4±18.8 U and in heart failure only it was 29.4±8.5 U. Intensification of β-adrenoreactivity was found to be proportional to worsening of clinical features of chronic heart failure in all patients that was more prominent in patients with pulmonary disease. Responders with heart failure in association with chronic obstructive pulmonary disease had higher values of β-adrenoreactivity of cell membranes more frequently.

Conclusion. The results of our investigation confirm increased activity of sympathetic system in heart failure and concominant chronic obstructive pulmonary disease that worsens clinical manifestations of heart failure.

Keywords

chronic heart failure / chronic obstructive pulmonary disease / β-adrenoreactivity

References

[1] Булашова О.В., Малкова М.И. Адренореактивность как прогностический критерий периоперационных кардиальных осложнений при внесердечных операциях. Казанский мед. ж. 2012; 93 (2): 177-181.

[2] Булашова О.В., Ослопов В.Н., Хазова Е.В. Адренореактивность у больных с хронической сердечной недостаточностью. Практич. мед. 2011; 4 (52): 72-74.

[3] Бунова С.С., Остапенко В.А., Николаев Н.А. Артериальная гипертония и адренореактивность: особенности у больных с ожирением. Бюлл. СО РАМН. 2008; 1 (129): 77-81.

[4] Верткин А.Л., Скотников А.С., Тихоновская Е.Ю. и др. Коморбидность при ХОБЛ: роль хронического системного воспаления. Рос. мед. ж. 2014; (11): 811-816.

[5] Воробьёва О.В., Дмитриев А.О. Прогнозирование течения и исхода атеротромботического инсульта на основании оценки активности адренорецепторов эритроцитов и клинической картины. Ж. неврол. и психиатр. 2014; 8 (2): 52-56.

[6] Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (IV пересмотр). Ж. серд. недост. 2013; 14 (7): 379-472.

[7] Селезнёва Е.Л., Жданова Т.В. Роль нейрогуморальной активации в развитии АГ и хронической обструктивной болезни лёгких. Врач. 2015; (2): 5-8.

[8] Ситникова М.Ю., Юрченко А.В., Лясникова Е.А. и др. Опыт создания и первые результаты работы российского госпитального регистра хронической сердечной недостаточности в трёх субъектах Российской Федерации. Трансляционная мед. 2014; (1): 73-81.

[9] Стрюк Р.И., Длусская И.Г. Адренореактивность и сердечно-сосудистая система. М.: Медицина. 2003; 160 с.

[10] Anthonisen N., Skeans M., Wise R. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142 (4): 233-239. http://dx.doi.org/10.7326/0003-4819-142-4-200502150-00005

[11] Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370: 741-750. http://dx.doi.org/10.1016/S0140-6736(07)61377-4

[12] Chuchalin A.G., Khaltaev N., Antonov N.S. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963-974. http://dx.doi.org/10.2147/COPD.S67283

[13] Rutten F.H., Cramer M.J., Grobbee D.E. et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur. Heart J. 2005; 26 (18): 1887-1894. http://dx.doi.org/10.1093/eurheartj/ehi291

[14] Seferovic P.M., Stroerk S., Filippatos G. et al. Organization of HF management in European Society of Cardiology member chantries: survey of Heart failure Association of the European Society of Cardiology in collaboration with Heart Failure National Societies. Working groups. Eur. J. Heart Failure. 2013; 15 (9): 947-959. http://dx.doi.org/10.1093/eurjhf/hft092

[15] Van Gestel A.J., Kohler M., Clarenbach C.F. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Discov. Med. 2012; 14 (79): 359-368.

RIGHTS & PERMISSIONS

Gazizyanova V.M., Bulashova O.V., Nasybullina A.A., Shaykhutdinova Z.A., Podol’skaya A.A.